: Epicardial adipose tissue surrounds and infiltrates the heart. Epicardial fat displays unique anatomic, genetic, and biomolecular properties. People with obesity and in particular, those with abdominal obesity and associated type 2 diabetes mellitus, have an increased amount of epicardial adipose tissue (EAT). Epicardial fat works well as therapeutic target due to its fast-responding metabolism, organ fat specificity, and easy measurability. Epicardial fat responds to thiazolidinediones (TZD), glucagon-like peptide 1-receptor agonists (GLP1A), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and statins. Modulating epicardial fat morphology and genetic profile with targeted pharmacological agents suggests novel strategies in the pharmacotherapy of diabetes and obesity.

Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy / G. Iacobellis, S. Basilico, A.E. Malavazos (HANDBOOK OF EXPERIMENTAL PHARMACOLOGY). - In: From Obesity to Diabetes / [a cura di] J.E. Barrett. - [s.l] : Springer, 2022. [10.1007/164_2021_577]

Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy

Basilico, Sara;Malavazos, Alexis Elias
2022

Abstract

: Epicardial adipose tissue surrounds and infiltrates the heart. Epicardial fat displays unique anatomic, genetic, and biomolecular properties. People with obesity and in particular, those with abdominal obesity and associated type 2 diabetes mellitus, have an increased amount of epicardial adipose tissue (EAT). Epicardial fat works well as therapeutic target due to its fast-responding metabolism, organ fat specificity, and easy measurability. Epicardial fat responds to thiazolidinediones (TZD), glucagon-like peptide 1-receptor agonists (GLP1A), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and statins. Modulating epicardial fat morphology and genetic profile with targeted pharmacological agents suggests novel strategies in the pharmacotherapy of diabetes and obesity.
Dipeptidyl peptidase-4 inhibitors; Epicardial adipose tissue: pharmaceutical target; Epicardial fat; Glucagon-like peptide 1-receptor agonists; Sodium glucose co-transporter 2 inhibitors; Statins; Thiazolidinediones
Settore MED/13 - Endocrinologia
Book Part (author)
File in questo prodotto:
File Dimensione Formato  
Iacobellis2022_Chapter_TargetingEpicardialFatInObesit.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 301.5 kB
Formato Adobe PDF
301.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/911027
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact